Combined use of multi-day doses of palonosetron and aprepitant with low doses dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous stem cell transplant: A pilot study

Trial Profile

Combined use of multi-day doses of palonosetron and aprepitant with low doses dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous stem cell transplant: A pilot study

Completed
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Aprepitant (Primary) ; Palonosetron (Primary) ; Dexamethasone
  • Indications Chemotherapy-induced nausea and vomiting
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00600353).
    • 05 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov (NCT00600353).
    • 05 May 2010 Actual end date (1 JAn 2010) added as reported by ClinicalTrials.gov (NCT00600353).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top